공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

변연부 림프종 : 시장 분석, 역학, 시장 예측(2030년)

Marginal Zone Lymphoma Market Insight, Epidemiology and Market Forecast -2030

리서치사 DelveInsight Business Research LLP
발행일 On Demand Report 상품 코드 980948
페이지 정보 영문 279 Pages
가격
US $ 6,950 ₩ 8,062,000 PDF (Single User License)
US $ 13,900 ₩ 16,125,000 PDF (Site License)
US $ 20,850 ₩ 24,188,000 PDF (Global License)


변연부 림프종 : 시장 분석, 역학, 시장 예측(2030년) Marginal Zone Lymphoma Market Insight, Epidemiology and Market Forecast -2030
발행일 : On Demand Report 페이지 정보 : 영문 279 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 주요 7개국(미국, 유럽 주요 5개국(EU5 : 프랑스·독일·이탈리아·스페인·영국), 일본)에서 변연부 림프종(MZL)의 역학적 동향과 향후 시장 전망에 대해 분석했으며, 질환의 개요 및 시장의 기본 구조, 현재의 치료법과 미충족 요구, 환자 수의 동향 전망, 출시/임상시험중인 치료제의 개요, 세계 전체/각국의 시장 규모(과거 3년간·향후 11년간), 주요 시장 촉진·억제요인 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 변연부 림프종(MZL) : 개요

제3장 변연부 림프종(MZL) : 시장 개요

  • 전체적인 시장 점유율 구조(2017년)
  • 전체적인 시장 점유율 구조(2030년)

제4장 질환 배경과 개요 : 변연부 림프종(MZL)

  • 서론
  • MZLB 세포 림프종의 병인에서 감염성 병인의 역할
    • 다양한 해부학적 부위에서의 만성 염증 및 감염성 병원체와 MZL와의 관련
    • H. pylori 및 위 MALT 림프종 병원성 모델
    • C.psittaci 및 안와 부속기 MZL
    • 피부 MZL의 B. burgdorferi
    • 면역 증식성 소장 질환 및 C. jejuni
    • A. xyloxidans와 폐 MALT 림프종
    • C형 간염 바이러스와 MZL
  • 변연부 림프종의 생물학적 특성
    • NF-KB 신호전달
    • NOTCH 시그널링
    • KLF2
    • PTPRD
    • 크로마틴 리모델링과 에피게놈 조절
    • 항원 자극
  • MZL의 진단
    • 맥아
    • 절점 MZL
    • 비장 MZL
  • MZL의 진단을 위한 ESMO 임상 진료 가이드라인
    • 병기 분류와 리스크 평가

제5장 증례 보고

  • 준비 두개내 경막 변연부 림프종 : 증례 보고
  • 상직근이 관여하는 결절외변연대 B세포 림프종 : 임상 병리학적 증례 보고
  • 원발성 척추 변연부 림프종 : 증례 보고와 문헌 리뷰

제6장 역학과 환자 인구

  • 주요 분석 결과
  • 전문가(KOL)의 견해
  • 분석 방법
  • 비호지킨림프종(NHL)의 환자 총수(주요 7개국의 경우)
  • 변연부 림프종(MZL)의 진단 환자 수(주요 7개국의 경우)

제7장 미국의 역학적 동향

  • 전제조건과 이론적 근거
    • 비호지킨림프종(NHL)의 발증 건수 - 총수
    • 변연부 림프종(MZL)의 발증 건수 - 총수
    • MZL의 발증 건수 : 성별
    • MZL의 발증 건수 : 서브타입별
    • MZL의 발증 건수 : 병기별

제8장 유럽 주요 5개국(EU5)의 역학적 동향

  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국

제9장 일본의 역학적 동향

제10장 현재의 치료 방법과 진료 행위

  • EMZL(절외 MZL)
  • SMZL(비장 MZL)
  • 절점 MZL
  • 재발성 질환
  • ESMO에 의한 MZL의 진단·치료·팔로우 업용 가이드라인의 공개
  • 치료 알고리즘

제11장 미충족 요구

제12장 출시 의약품

  • Revlimid(lenalidomide)와 리툭시맙의 병용 : Celgene Corporation, Bristol-Myers Squibb
    • 약물 설명
    • 규제 마일스톤
    • 임상 개발
    • 안전성과 유효성
    • 제품 개요
  • Imbruvica(ibrutinib) : AbbVie, Janssen Biotech

제13장 새로운 치료제

  • 키 크로스 경쟁
  • Umbralisib(TGR-1202) : TG Therapeutics
    • 제품 설명
    • 기타 개발 활동
    • 임상 개발
    • 안전성과 유효성
    • 제품 개요
  • Aliqopa(Copanlisib) : Bayer
  • Ublituximab : TG Therapeutics
  • Obinutuzumab : Roche Pharma
  • Yescarta(axicabtagene ciloleucel) : Gilead Sciences
  • Keytruda(Pembrolizumab) : Merck Sharp & Dohme
  • CLR 131 : Cellectar Biosciences
  • Parsaclisib : Innovent Biologics
  • Nivolumab(Oppdivo) : Bristol-Myers Squibb
  • Calquence(acalabrutinib) : Astrazeneca
  • Betalutin(177Lu-satetraxetan-lilotomab) : Nordic Nanovector
  • Navitoclax(ABT-263) : AbbVie
  • Orelabrutinib(ICP-022) : InnoCare Pharma
  • M7583 : Merck KGaA
  • ARQ 531 : ArQule/Merck
  • Duvelisib : Verastem/Secura Bio
  • Zanubrutinib : BeiGene
  • Zandelisib : MEI Pharma
  • ALT-803 : NantKwest/ImmunityBio
  • LOXO-305 : Loxo Oncology/Eli Lilly
  • SD-101 : TriSalus Life Sciences

제14장 환자 여정

제15장 변연부 림프종(MZL) : 주요 7개국 분석

  • 주요 조사 결과
  • 시장 조사 방법
  • 변연부 림프종(MZL)의 전체적인 시장 규모
  • 시장 규모 : 치료제별
    • 1차 MZL 치료제의 시장 규모
    • 2차 MZL 치료제의 시장 규모
    • 3차 MZL 치료제의 시장 규모

제16장 새로운 치료제의 가능성

제17장 주요 시장 예측의 전제조건

제18장 주요 7개국 시장 전망

제19장 미국

  • 미국의 시장 규모
    • 변연부 림프종(MZL)의 전체적인 시장 규모
    • 시장 규모 : 치료제별

제20장 유럽 주요 5개국(EU5)

  • 독일의 시장 규모
    • 변연부 림프종(MZL)의 전체적인 시장 규모
    • 시장 규모 : 치료제별
  • 프랑스의 시장 규모
    • 시장 규모 : 치료제별
  • 이탈리아의 시장 규모
  • 스페인의 시장 규모
  • 영국의 시장 규모
    • 변연부 림프종(MZL)의 전체적인 시장 규모
    • 시장 규모 : 치료제별

제21장 : 일본

  • 일본의 시장 규모
    • 변연부 림프종(MZL)의 전체적인 시장 규모
    • 시장 규모 : 치료제별

제22장 시장 촉진요인

제23장 시장 저해요인

제24장 SWOT 분석

제25장 상환과 시장 접근

제26장 공인 시설

제27장 부록

제28장 DelveInsight의 서비스 내용

제29장 면책사항

제30장 DelveInsight 소개

KSA 21.01.26

List of Tables

  • Table 1: Summary of Marginal Zone Lymphoma (MZL), Market, Epidemiology and Key Events (2017-2030)
  • Table 2: Total Incident Cases of Non-Hodgkin lymphoma (NHL) in the 7MM (2017-2030)
  • Table 3: Total Incident Cases of Marginal Zone Lymphoma (MZL) in the 7MM (2017-2030)
  • Table 4: Major Sources Used
  • Table 5: Total incident cases of Non-Hodgkin lymphoma (NHL) in the United States (2017-2030)
  • Table 6: Total incident cases of Marginal Zone Lymphoma (MZL) in the United States (2017-2030)
  • Table 7: Gender-specific incident cases of MZL in the United States (2017-2030)
  • Table 8: Subtype-specific incident cases of MZL in the United States (2017-2030)
  • Table 9: Stage-specific incident cases of MZL in the United States (2017-2030)
  • Table 10: Total incident cases of Non-Hodgkin lymphoma (NHL) in Germany (2017-2030)
  • Table 11: Total incident cases of Marginal Zone Lymphoma (MZL) in Germany (2017-2030)
  • Table 12: Gender-specific incident cases of MZL in Germany (2017-2030)
  • Table 13: Subtype-specific incident cases of MZL in Germany (2017-2030)
  • Table 14: Stage-specific incident cases of MZL in Germany (2017-2030)
  • Table 15: Total incident cases of Non-Hodgkin lymphoma (NHL) in France (2017-2030)
  • Table 16: Total incident cases of Marginal Zone Lymphoma (MZL) in France (2017-2030)
  • Table 17: Gender-specific incident cases of MZL in France (2017-2030)
  • Table 18: Subtype-specific incident cases of MZL in France (2017-2030)
  • Table 19: Stage-specific incident cases of MZL in France (2017-2030)
  • Table 20: Total incident cases of Non-Hodgkin lymphoma (NHL) in Italy (2017-2030)
  • Table 21: Total incident cases of Marginal Zone Lymphoma (MZL) in Italy(2017-2030)
  • Table 22: Gender-specific incident cases of MZL in Italy (2017-2030)
  • Table 23: Type-specific incident cases of MZL in Italy (2017-2030)
  • Table 24: Stage-specific incident cases of MZL in Italy (2017-2030)
  • Table 25: Total incident cases of Non-Hodgkin lymphoma (NHL) in Spain (2017-2030)
  • Table 26: Total incident cases of Marginal Zone Lymphoma (MZL) in Spain (2017-2030)
  • Table 27: Gender-specific incident cases of MZL in Spain (2017-2030)
  • Table 28: Subtype-specific incident cases of MZL in Spain (2017-2030)
  • Table 29: Stage-specific incident cases of MZL in Spain (2017-2030)
  • Table 30: Total incident cases of Non-Hodgkin lymphoma (NHL) in the UK (2017-2030)
  • Table 31: Total incident cases of Marginal Zone Lymphoma (MZL) in the UK (2017-2030)
  • Table 32: Gender-specific incident cases of MZL in the UK (2017-2030)
  • Table 33: Subtype-specific incident cases of MZL in the UK (2017-2030)
  • Table 34: Stage-specific incident cases of MZL in the UK (2017-2030)
  • Table 35: Total incident cases of Non-Hodgkin lymphoma (NHL) in Japan (2017-2030)
  • Table 36: Total incident cases of Marginal Zone Lymphoma (MZL) in Japan(2017-2030)
  • Table 37: Gender-specific incident cases of MZL in Japan (2017-2030)
  • Table 38: Subtype-specific incident cases of MZL in Japan (2017-2030)
  • Table 39: Stage-specific incident cases of MZL in Japan (2017-2030)
  • Table 40: Rituximab Plus Lenalidomide, Clinical Trial Description, 2020
  • Table 41: Imbruvica (ibrutinib), Clinical Trial Description, 2020
  • Table 42: Comparison of emerging drugs under development
  • Table 43: Comparison of emerging drugs under early phase of development for MZL
  • Table 44: Umbralisib, Clinical Trial Description, 2020
  • Table 45: Aliqopa (Copanlisib), Clinical Trial Description, 2020
  • Table 46: Ublituximab, Clinical Trial Description, 2020
  • Table 47: Obinutuzumab Clinical Trial Description, 2020
  • Table 48: Yescarta (axicabtagene ciloleucel), Clinical Trial Description, 2020
  • Table 49: Keytruda (Pembrolizumab), Clinical Trial Description, 2020
  • Table 50: CLR 131, Clinical Trial Description, 2020
  • Table 51: Parsaclisib, Clinical Trial Description, 2020
  • Table 52: Nivolumab, Clinical Trial Description, 2020
  • Table 53: Calquence, Clinical Trial Description, 2020
  • Table 54: Betalutin, Clinical Trial Description, 2020
  • Table 55: ABT-263, Clinical Trial Description, 2020
  • Table 56: ICP-022, Clinical Trial Description, 2020
  • Table 57: M7583, Clinical Trial Description, 2020
  • Table 58: ARQ 531, Clinical Trial Description, 2020
  • Table 59: Duvelisib, Clinical Trial Description, 2020
  • Table 60: Zanubrutinib, Clinical Trial Description, 2020
  • Table 61: Zandelisib, Clinical Trial Description, 2020
  • Table 62: ALT-803, Clinical Trial Description, 2020
  • Table 63: LOXO-305, Clinical Trial Description, 2020
  • Table 64: SD-101, Clinical Trial Description, 2020
  • Table 65: Market Size of Marginal Zone Lymphoma (MZL) in the 7MM in USD Million (2017-2030)
  • Table 66: Market Size of MZL by First-line therapies in the 7MM, in USD Million (2017-2030)
  • Table 67: Market Size of MZL by Second-line therapies in the 7MM, in USD Million (2017-2030)
  • Table 68: Market Size of MZL by Third-line therapies in the 7MM, in USD Million (2017-2030)
  • Table 69: Key market forecast assumptions for Umbralisib (TGR-1202)
  • Table 70: Key market forecast assumptions for Duvelisib
  • Table 71: Key market forecast assumptions for Ublituximab
  • Table 72: Key market forecast assumptions for Aliqopa (copanlisib)
  • Table 73: Key market forecast assumptions for Calquence (Acalabrutinib)
  • Table 74: Key market forecast assumptions for Zanubrutinib (BGB-3111)
  • Table 75: Key market forecast assumptions for Zandelisib (ME-401)
  • Table 76: Key market forecast assumptions for Parsaclisib (IBI-376)
  • Table 77: Key market forecast assumptions for Yescarta (axicabtagene ciloleucel)
  • Table 78: Key market forecast assumptions for Betalutin
  • Table 79: Key market forecast assumptions for CLR 131
  • Table 80: The US Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017-2030)
  • Table 81: Market Size of MZL by First-line therapies in the US, in USD Million (2017-2030)
  • Table 82: Market Size of MZL by Second-line therapies in the US, in USD Million (2017-2030)
  • Table 83: Market Size of MZL by Third-line therapies in the US, in USD Million (2017-2030)
  • Table 84: Germany Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017-2030)
  • Table 85: Market Size of MZL by First-line therapies in Germany, in USD Million (2017-2030)
  • Table 86: Market Size of MZL by Second-line therapies in Germany, in USD Million (2017-2030)
  • Table 87: Market Size of MZL by Third-line therapies in Germany, in USD Million (2017-2030)
  • Table 88: France Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017-2030)
  • Table 89: Market Size of MZL by First-line therapies in France, in USD Million (2017-2030)
  • Table 90: Market Size of MZL by Second-line therapies in France, in USD Million (2017-2030)
  • Table 91: Market Size of MZL by Third-line therapies in France, in USD Million (2017-2030)
  • Table 92: Italy Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017-2030)
  • Table 93: Market Size of MZL by First-line therapies in Italy, in USD Million (2017-2030)
  • Table 94: Market Size of MZL by Second-line therapies in Italy, in USD Million (2017-2030)
  • Table 95: Market Size of MZL by Third-line therapies in Italy, in USD Million (2017-2030)
  • Table 96: Spain Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017-2030)
  • Table 97: Market Size of MZL by First-line therapies in Spain, in USD Million (2017-2030)
  • Table 98: Market Size of MZL by Second-line therapies in Spain, in USD Million (2017-2030)
  • Table 99: Market Size of MZL by Third-line therapies in Spain, in USD Million (2017-2030)
  • Table 100: The UK Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017-2030)
  • Table 101: Market Size of MZL by First-line therapies in the UK, in USD Million (2017-2030)
  • Table 102: Market Size of MZL by Second-line therapies in the UK, in USD Million (2017-2030)
  • Table 103: Market Size of MZL by Third-line therapies in the UK, in USD Million (2017-2030)
  • Table 104: Japan Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017-2030)
  • Table 105: Market Size of MZL by First-line therapies in Japan, in USD Million (2017-2030)
  • Table 106: Market Size of MZL by Second-line therapies in Japan, in USD Million (2017-2030)
  • Table 107: Market Size of MZL by Third-line therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1: H. pylori (HP)-induced lymphomagenesis
  • Figure 2: Summary of the main genetic and biologic features characterizing marginal zone lymphomas
  • Figure 3: Endoscopic Ultrasonography Staging of Gastric MALT Lymphoma
  • Figure 4: KOL Views
  • Figure 5: Total Incident Cases of Non-Hodgkin lymphoma (NHL) in the 7MM (2017-2030)
  • Figure 6: Total Incident Cases of Marginal Zone Lymphoma (MZL) in the 7MM (2017-2030)
  • Figure 7: Global Heat Map of NHL
  • Figure 8: Total incident cases of Non-Hodgkin lymphoma (NHL) in the United States (2017-2030)
  • Figure 9: Total incident cases of Marginal Zone Lymphoma (MZL) in the United States (2017-2030)
  • Figure 10: Gender-specific incident cases of MZL in the United States (2017-2030)
  • Figure 11: Subtype -specific incident cases of MZL in the United States (2017-2030)
  • Figure 12: Stage-specific incident cases of MZL in the United States (2017-2030)
  • Figure 13: Total incident cases of Non-Hodgkin lymphoma (NHL) in Germany (2017-2030)
  • Figure 14: Total incident cases of Marginal Zone Lymphoma (MZL) in Germany (2017-2030)
  • Figure 15: Gender-specific incident cases of MZL in Germany (2017-2030)
  • Figure 16: Subtype-specific incident cases of MZL in Germany (2017-2030)
  • Figure 17: Stage-specific incident cases of MZL in Germany (2017-2030)
  • Figure 18: Total incident cases of Non-Hodgkin lymphoma (NHL) in France (2017-2030)
  • Figure 19: Total incident cases of Marginal Zone Lymphoma (MZL) in France (2017-2030)
  • Figure 20: Gender-specific incident cases of MZL in France (2017-2030)
  • Figure 21: Subtype-specific incident cases of MZL in France (2017-2030)
  • Figure 22: Stage-specific incident cases of MZL in France (2017-2030)
  • Figure 23: Total incident cases of Non-Hodgkin lymphoma (NHL) in Italy (2017-2030)
  • Figure 24: Total incident cases of Marginal Zone Lymphoma (MZL) in Italy (2017-2030)
  • Figure 25: Gender-specific incident cases of MZL in Italy (2017-2030)
  • Figure 26: Subtype-specific incident cases of MZL in Italy (2017-2030)
  • Figure 27: Stage-specific incident cases of MZL in Italy (2017-2030)
  • Figure 28: Total incident cases of Non-Hodgkin lymphoma (NHL) in Spain (2017-2030)
  • Figure 29: Total incident cases of Marginal Zone Lymphoma (MZL) in Spain (2017-2030)
  • Figure 30: Gender-specific incident cases of MZL in Spain (2017-2030)
  • Figure 31: Subtype-specific incident cases of MZL in Spain (2017-2030)
  • Figure 32: Stage-specific incident cases of MZL in Spain (2017-2030)
  • Figure 33: Total incident cases of Non-Hodgkin lymphoma (NHL) in the UK (2017-2030)
  • Figure 34: Total incident cases of Marginal Zone Lymphoma (MZL) in the UK (2017-2030)
  • Figure 35: Gender-specific incident cases of MZL in the UK (2017-2030)
  • Figure 36: Subtype-specific incident cases of MZL in the UK (2017-2030)
  • Figure 37: Stage-specific incident cases of MZL in the UK (2017-2030)
  • Figure 38: Total incident cases of Non-Hodgkin lymphoma (NHL) in Japan (2017-2030)
  • Figure 39: Total incident cases of Marginal Zone Lymphoma (MZL) in Japan (2017-2030)
  • Figure 40: Gender-specific incident cases of MZL in Japan (2017-2030)
  • Figure 41: Subtype-specific incident cases of MZL in Japan (2017-2030)
  • Figure 42: Stage-specific incident cases of MZL in Japan (2017-2030)
  • Figure 43: Classification of MZL
  • Figure 44: Treatment algorithm for localized gastric MZL
  • Figure 45: Treatment algorithms for advanced gastric MZL and non-gastric EMZ
  • Figure 46: Treatment algorithm for gastric MALT lymphoma
  • Figure 47: Treatment of splenic MZL
  • Figure 48: Treatment of Non-gastric MALT Lymphoma
  • Figure 49: Gastric MALT Lymphoma
  • Figure 50: Splenic MZL
  • Figure 51: Non-gastric MALT Lymphoma
  • Figure 52: Unmet needs
  • Figure 53: Market Size of Marginal Zone Lymphoma (MZL) in the 7MM in USD Million (2017-2030)
  • Figure 54: Market Size of MZL by First-line therapies in the 7MM, in USD Million (2017-2030)
  • Figure 55: Market Size of MZL by Second-line therapies in the 7MM, in USD Million (2017-2030)
  • Figure 56: Market Size of MZL by Third-line therapies in the 7MM, in USD Million (2017-2030)
  • Figure 57: Market Size of Marginal Zone Lymphoma (MZL) in the US, USD Millions (2017-2030)
  • Figure 58: Market Size of MZL by First-line Therapies in the US, in USD Million (2017-2030)
  • Figure 59: Market Size of MZL by Second-line Therapies in the US, in USD Million (2017-2030)
  • Figure 60: Market Size of MZL by Third-line Therapies in the US, in USD Million (2017-2030)
  • Figure 61: Market Size of Marginal Zone Lymphoma (MZL) in Germany, USD Millions (2017-2030)
  • Figure 62: Market Size of MZL by First-line Therapies in Germany, in USD Million (2017-2030)
  • Figure 63: Market Size of MZL by Second-line Therapies in Germany, in USD Million (2017-2030)
  • Figure 64: Market Size of MZL by Third-line Therapies in Germany, in USD Million (2017-2030)
  • Figure 65: Market Size of Marginal Zone Lymphoma (MZL) in France, USD Millions (2017-2030)
  • Figure 66: Market Size of MZL by First-line Therapies in France, in USD Million (2017-2030)
  • Figure 67: Market Size of MZL by Second-line Therapies in France, in USD Million (2017-2030)
  • Figure 68: Market Size of MZL by Third-line Therapies in France, in USD Million (2017-2030)
  • Figure 69: Market Size of Marginal Zone Lymphoma (MZL) in Italy, USD Millions (2017-2030)
  • Figure 70: Market Size of MZL by First-line Therapies in Italy, in USD Million (2017-2030)
  • Figure 71: Market Size of MZL by Second-line Therapies in Italy, in USD Million (2017-2030)
  • Figure 72: Market Size of MZL by Third-line Therapies in Italy, in USD Million (2017-2030)
  • Figure 73: Market Size of Marginal Zone Lymphoma (MZL) in Spain, USD Millions (2017-2030)
  • Figure 74: Market Size of MZL by First-line Therapies in Spain, in USD Million (2017-2030)
  • Figure 75: Market Size of MZL by Second-line Therapies in Spain, in USD Million (2017-2030)
  • Figure 76: Market Size of MZL by Third-line Therapies in Spain, in USD Million (2017-2030)
  • Figure 77: Market Size of Marginal Zone Lymphoma (MZL) in the UK, USD Millions (2017-2030)
  • Figure 78: Market Size of MZL by First-line Therapies in the UK, in USD Million (2017-2030)
  • Figure 79: Market Size of MZL by Second-line Therapies in in the UK, in USD Million (2017-2030)
  • Figure 80: Market Size of MZL by Third-line Therapies in the UK, in USD Million (2017-2030)
  • Figure 81: Market Size of Marginal Zone Lymphoma (MZL) in Japan, USD Millions (2017-2030)
  • Figure 82: Market Size of MZL by First-line Therapies in Japan, in USD Million (2017-2030)
  • Figure 83: Market Size of MZL by Second-line Therapies in Japan, in USD Million (2017-2030)
  • Figure 84: Market Size of MZL by Third-line Therapies in Japan, in USD Million (2017-2030)
  • Figure 85: Market Drivers
  • Figure 86: Market Barriers
  • Figure 87: SWOT Analysis of Marginal Zone Lymphoma (MZL)

DelveInsight's 'Marginal Zone Lymphoma-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the MZL, historical and forecasted epidemiology as well as the MZL market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Marginal Zone Lymphoma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM MZL market size from 2017 to 2030. The Report also covers current MZL treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Marginal Zone Lymphoma Disease Understanding and Treatment Algorithm

Marginal Zone Lymphoma Overview

Marginal zone B-cell lymphoma or Marginal Zone Lymphoma (MZL) is a group of indolent (slow-growing) NHL B-cell lymphomas, which account for approximately 5-17% of all NHL cases. In the World Health Organization classification, there are three different MZL entities with specific diagnostic criteria, behavior, and therapeutic implications: the extranodal MZL of mucosa-associated lymphoid tissue (MALT) type (MALT lymphoma), the splenic MZL (SMZL), and the nodal MZL (NMZL).

Extranodal marginal zone B-cell lymphoma, also known as mucosa-associated lymphoid tissue (MALT) lymphoma: This is the most common type of marginal zone lymphoma. It starts in places other than the lymph nodes (extranodal). Nodal MZL (sometimes called monocytoid B-cell lymphoma) occurs within the lymph nodes and accounts for about 10% of all MZL cases. In most cases, it is not known what causes nodal MZL. It is more common in people who have been infected with the hepatitis C virus and some autoimmune conditions than others. Splenic MZL occurs most often in the spleen and blood. It has been associated with hepatitis C virus (HCV) infection. It is a low-grade B-cell non-Hodgkin's lymphoma characterized by massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes, and indolent clinical course.

Marginal Zone Lymphoma Diagnosis

To make a diagnosis, the doctor would need to stage the disease. Staging is also how the doctor decides the right treatment. It involves evaluating the location and size of the tumors and determining whether cancer has spread to other parts of the body. The diagnosis can be established based on the endoscopic appearance. The endoscopist must take specimens from the antrum and the corpus for the urease test. If the examined segments are unsuspicious, a biopsy must be performed from each quadrant of the fundus, the corpus, and the antrum and ten biopsies if they are suspicious, to request a histological workup.

Continued in the report…..

Marginal Zone Lymphoma Treatment

Treatment selection for a patient with Marginal Zone Lymphoma (MZL) depends on the type, stage, and location of the disease. Since gastric MALT lymphoma is often the result of an infection with H. pylori, the initial treatment is antibiotic therapy, usually combined with proton pump inhibitors (PPIs). The most commonly used regimen is triple therapy: a proton pump inhibitor (omeprazole) in association with amoxicillin and clarithromycin. Metronidazole can be substituted for amoxicillin in penicillin-allergic individuals. If the lymphoma relapses (disease returns after treatment) or becomes refractory (disease does not respond to treatment) after antibiotic therapy, there are many additional treatment options available, including rituximab, radiation therapy, and surgery. For SMZL, the recognized therapeutic options are splenectomy, chemotherapy (ChT), rituximab alone, or rituximab plus chemotherapy. Nodal MZL usually responds well to chemotherapy. It may be given as a single drug or a combination of drugs and is often given with a targeted therapy drug. Single drugs that may be used for nodal MZL are fludarabine (Fludara), bendamustine (Treanda). Combinations of chemotherapy drugs that may be used are: CHOP,R-CHOP,CVP,R-CVP and BR.

Marginal Zone Lymphoma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of Non-Hodgkin lymphoma, Total incident cases of Marginal Zone Lymphoma, Gender-specific incident cases of MZL, Subtype-specific incident cases of MZL and Stage-specific incident cases of MZL scenario of MZL in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017-2030.

Key Findings

  • The total incident population of Non-Hodgkin lymphoma (NHL) in the 7MM was anticipated to be 166,967 in 2017.
  • The total incident population of MZL in the 7MM was anticipated to be 21,284 in 2017 and is expected to rise by 2030.
  • According to the estimates, the highest market size of Marginal Zone Lymphoma (MZL) was found in the United States, followed by Japan
  • The epidemiological model of DelveInsight estimates a higher proportion of MZL cases was found in stage III as compared to other stages in the United States. In 2017, stage I, stage II, and stage III MZL incident cases were 1,416, 465, and 5,307 respectively, in the US.

Marginal Zone Lymphoma Epidemiology

The epidemiology segment also provides the MZL epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Marginal Zone Lymphoma Drug Chapters

The drug chapter segment of the MZL report encloses the detailed analysis of MZL marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the MZL clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

Marginal Zone Lymphoma Marketed Drugs

Revlimid (lenalidomide) in combination with rituximab: Celgene Corporation, Bristol-Myers Squibb

Revlimid is an immune-modulating therapy with proven anti-myeloma efects. It is an oral therapy that was shown to work in three ways in animal models and in vitro, it helps the immune system recognize and destroy myeloma cells. It has the ability to targets and kills myeloma cells and helps prevent new myeloma cell growth by starving them of blood. In May 2019, FDA approved lenalidomide Revlimid in combination with a rituximab product for previously treated FL and previously-treated MZL.

Products detail in the report…

Imbruvica (ibrutinib): AbbVie, Janssen Biotech

Ibrutinib is a small-molecule inhibitor of BTK. The drug forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK's role in signaling through the B-cell surface receptors results in the activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.

The recommended dose of Imbruvica for MCL and MZL is 560 mg orally once daily until disease progression or unacceptable toxicity.

Products detail in the report…

Marginal Zone Lymphoma Emerging Drugs

Umbralisib (TGR-1202): TG Therapeutics

Umbralisib (TGR-1202) is an orally administered, investigational dual inhibitor of PI3K delta and CK1 epsilon, which is administered orally once daily. The phosphoinositide-3-kinases (PI3Ks) are a family of enzymes involved in many important cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking, and immunity. There are four isoforms of PI3K (alpha, beta, delta, and gamma), of which the delta isoform is highly expressed in hematopoietic cells. Dysregulation of the PI3K pathway is among one of the most commonly mutated pathways across all of cancer biology.

Currently, TG Therapeutics is investigating the drug in Phase II/III clinical in a combination of ublituximab, with or without Bendamustine, and TGR-1202 alone in patients with previously treated non-Hodgkin's lymphoma (NHL).

Products detail in the report…

Aliqopa (Copanlisib): Bayer

Aliqopa (Copanlisib) is an intravenously administered, small molecule with inhibitory activity against all four isoforms including the PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells. The PI3K pathway is involved in cell growth, survival, and metabolism, and its dysregulation plays an important role in the development of lymphoma. The drug is also the only PI3K inhibitor administered intravenously on an intermittent schedule: on days 1, 8, and 15 of a 28-day treatment cycle. Treatment should be continued until disease progression or unacceptable toxicity. Copanlisib is currently approved in the US and Taiwan under the brand name Aliqopa for relapsed follicular lymphoma (FL). In September 2017, the US FDA granted accelerated approval to the drug for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. The drug is currently in phase III for MZL.

Products detail in the report…

Ublituximab: TG Therapeutics

Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell, it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement-dependent cytotoxicity [CDC]), leading to the destruction of the cell. Additionally, ublituximab is uniquely designed, to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, has been shown to enhance the potency of ublituximab, especially the ADCC activity.

Products detail in the report…

List to be continued in the report…

Marginal Zone Lymphoma Market Outlook

A Marginal zone lymphomas (MZL) involves immune cells known as B-cells and accounts for between 5% and 17% of all non-Hodgkin lymphomas (NHL). The three main subtypes of MZL are extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal MZL, and splenic MZL. Of these, MALT lymphoma is the most common. The symptoms that may be caused by MZL depend on the type and location of the MZL. MALT lymphoma commonly involves the stomach, and patients may report abdominal pain, heartburn, and indigestion. MALT lymphoma may also develop in other areas of the body, such as the area around the eye, the salivary glands, or the lungs. Splenic MZL may be detected because of the enlargement of the spleen or abnormal blood cell counts. These types of lymphoma tend to be indolent (slow-growing).

Due to the slow nature of progression, most patients tend to present before developing significant complications. In the rare cases of life or organ-threatening MZL, high-dose corticosteroids (for example, dexamethasone 40 mg daily) can be used to temporize matters before starting more definitive (Immuno) chemotherapy or radiotherapy. Treatment of indolent lymphoma should be individualized according to the disease subtype, presentation, comorbid conditions, and patient preferences. When possible, the goal of therapy is to cure the disease and/or prolong survival. In all cases, the goal should be to improve quality of life; care must be taken to avoid overtreatment.

There are several different treatment approaches for SMZL, including single-agent rituximab, splenectomy, and traditional chemotherapy. For localized disease, local therapy is recommended such as triple therapy for H. pylori in gastric extranodal MZL, splenectomy for splenic MZL, and radiotherapy for nodal MZL. Also, most patients with nodal MZL present with advanced-stage disease and are not likely to achieve a cure, even with aggressive chemotherapy regimens. For a disseminated disease with a low tumor burden, a watch and wait or single-agent rituximab can be used. However, for symptomatic disease, a similar approach to follicular lymphoma (FL) can be used with chemoimmunotherapy approaches such as bendamustine and rituximab.

Patients with the relapsing disease after at least one CD20-based therapy have several recently approved chemotherapy-free options including B-cell receptor inhibitors such as ibrutinib (approved specifically in MZL) and immunomodulatory agents, such as lenalidomide and rituximab (FDA approved in MZL and FL). Phosphoinositide 3-kinase (PI3K) inhibitors have shown excellent activity in iNHL, specifically in MZL, with breakthrough designation status for copanlisib and umbralisib, allowing off label use of this class of agents in clinical practice.

Patients with early-stage MALT lymphoma with no underlying infectious etiology, or those for whom antibiotic therapy has failed, can be effectively managed with external beam radiotherapy. Rarely, marginal zone lymphoma can transform into a more aggressive lymphoma, typically DLBCL. These patients require aggressive therapy and may benefit from autologous stem cell transplantation. Although the aggressive subtype may resolve completely, patients are often left with a persistent low-grade lymphoma.

Key Findings

  • The market size of Marginal Zone Lymphoma (MZL) in the 7MM was estimated to be USD 427.16 million in 2017
  • Among the EU-5 countries, the UK has the highest and same market size of USD 43.85 million. The lowest market size was estimated in Spain with USD 10.65 million in 2017
  • Umbralisib (TGR-1202), Duvelisib, Ublituximab, Aliqopa (copanlisib), and Calquence (Acalabrutinib) are pipeline molecules that are expected to launch as second-line therapy in the forecast period (2020-2030)
  • The market size of first-line therapies in the 7MM was estimated to be USD 234.24 million in 2017.
  • The market size of second-line therapies was observed to be USD 162.33 million in the 7MM, in 2017, and the market size of third-line therapies was observed to be USD 30.59 million in the 7MM, in 2017.

The United States Market Outlook

This section provides the total MZL market size and; market size by line of therapies in the United States.

EU-5 Market Outlook

The total MZL market size and market size by line of therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total MZL market size and market size by line of therapies in Japan are provided.

Marginal Zone Lymphoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the MZL market or expected to get launched in the market during the study period 2017-2030. The analysis covers the MZL market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Marginal Zone Lymphoma Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Marginal Zone Lymphoma emerging therapies.

Reimbursement Scenario in Marginal Zone Lymphoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Marginal Zone Lymphoma market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of MZL, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the MZL epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for MZL is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the MZL market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM MZL market.

Report Highlights:

  • The robust pipeline with novel MOA and oral ROA, increasing prevalence, effectiveness of drugs as both mono and combination therapy will positively drive the MZL market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence MZL R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for MZL. Launch of emerging therapies will significantly impact the MZL market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Marginal Zone Lymphoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • MZL Pipeline Analysis
  • MZL Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Marginal Zone Lymphoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • MZL Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Marginal Zone Lymphoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions:

Market Insights:

  • What was the MZL market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the MZL total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest MZL market size during the forecast period (2020-2030)?
  • At what CAGR, the MZL market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the MZL market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the MZL market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of MZL?
  • What is the historical MZL patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of MZL at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MZL?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of MZL during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of MZL along with the approved therapy?
  • What are the current treatment guidelines for the treatment of MZL in the US and Europe?
  • What are the MZL marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of MZL?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of MZL?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the MZL therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for MZL and their status?
  • What are the key designations that have been granted for the emerging therapies for MZL?
  • What are the 7MM historical and forecasted market of MZL?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the MZL.
  • To understand the future market competition in the MZL market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for MZL in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the MZL market.
  • To understand the future market competition in the MZL market.

Table of Contents

1 Key Insights

2 Executive Summary of Marginal Zone Lymphoma (MZL)

3 Marginal Zone Lymphoma (MZL) Market Overview at a Glance

  • 3.1 Market Share (%) Distribution of MZL in 2017
  • 3.2 Market Share (%) Distribution of MZL in 2030

4 Disease Background and Overview: Marginal Zone Lymphoma (MZL)

  • 4.1 Introduction
  • 4.2 Role of infectious etiologies in the pathogenesis of MZLB-cell lymphomas
    • 4.2.1 Association of chronic inflammation and infectious agents with MZL at various anatomical sites
    • 4.2.2 The H. pylori and gastric MALT lymphoma pathogenetic model
    • 4.2.3 C. psittaci and ocular adnexal MZL
    • 4.2.4 B. burgdorferi in cutaneous MZL
    • 4.2.5 Immunoproliferative small intestinal disease and C. jejuni
    • 4.2.6 A. xyloxidans and pulmonary MALT lymphoma
    • 4.2.7 Hepatitis C virus and MZLs
  • 4.3 Biology of marginal zone lymphoma
    • 4.3.1 NF-KB signaling
    • 4.3.2 NOTCH signaling
    • 4.3.3 KLF2
    • 4.3.4 PTPRD
    • 4.3.5 Chromatin remodeling and epigenome regulation
    • 4.3.6 Antigen stimulation
  • 4.4 Diagnosis of MZL
    • 4.4.1 MALT
    • 4.4.2 Nodal MZL
    • 4.4.3 Splenic MZL
  • 4.5 ESMO Clinical Practice Guidelines for diagnosis of MZL
    • 4.5.1 Staging and risk assessment

5 Case Reports

  • 5.1 Preparatory intracranial dural marginal zone lymphoma: A Case Report
  • 5.2 An extranodal marginal zone B-cell lymphoma involving superior rectus muscle: A clinicopathological case report
  • 5.3 Primary spinal marginal zone lymphoma: Case report and review of the literature

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 KOL Views
  • 6.3 Epidemiology Methodology
  • 6.4 Total Incident Cases of Non-Hodgkin lymphoma (NHL) in the 7MM
  • 6.5 Total Incident Cases of Marginal Zone Lymphoma (MZL) in the 7MM

7 United States Epidemiology

  • 7.1 Assumptions and Rationale
    • 7.1.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in the United States
    • 7.1.2 Total incident cases of Marginal Zone Lymphoma (MZL) in the United States
    • 7.1.3 Gender-specific incident cases of MZL in the United States
    • 7.1.4 Subtype-specific incident cases of MZL in the United States
    • 7.1.5 Stage-specific incident cases of MZL in the United States

8 EU5 Epidemiology

  • 8.1 Assumptions and Rationale
  • 8.2 Germany Epidemiology
    • 8.2.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Germany
    • 8.2.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Germany
    • 8.2.3 Gender-specific incident cases of MZL in Germany
    • 8.2.4 Subtype-specific incident cases of MZL in Germany
    • 8.2.5 Stage-specific incident cases of MZL in Germany
  • 8.3 France Epidemiology
    • 8.3.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in France
    • 8.3.2 Total incident cases of Marginal Zone Lymphoma (MZL) in France
    • 8.3.3 Gender-specific incident cases of MZL in France
    • 8.3.4 Subtype-specific incident cases of MZL in France
    • 8.3.5 Stage-specific incident cases of MZL in France
  • 8.4 Italy Epidemiology
    • 8.4.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Italy
    • 8.4.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Italy
    • 8.4.3 Gender-specific incident cases of MZL in Italy
    • 8.4.4 Subtype-specific incident cases of MZL in Italy
    • 8.4.5 Stage-specific incident cases of MZL in Italy
  • 8.5 Spain Epidemiology
    • 8.5.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Spain
    • 8.5.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Spain
    • 8.5.3 Gender-specific incident cases of MZL in Spain
    • 8.5.4 Subtype-specific incident cases of MZL in Spain
    • 8.5.5 Stage-specific incident cases of MZL in Spain
  • 8.6 United Kingdom Epidemiology
    • 8.6.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in the United Kingdom
    • 8.6.2 Total incident cases of Marginal Zone Lymphoma (MZL) in the UK
    • 8.6.3 Gender-specific incident cases of MZL in the UK
    • 8.6.4 Subtype-specific incident cases of MZL in the UK
    • 8.6.5 Stage-specific incident cases of MZL in the UK

9 Japan Epidemiology

  • 9.1 Assumptions and Rationale
    • 9.1.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Japan
    • 9.1.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Japan
    • 9.1.3 Gender-specific incident cases of MZL in Japan
    • 9.1.4 Subtype-specific incident cases of MZL in Japan
    • 9.1.5 Stage-specific incident cases of MZL in Japan

10 Current Treatment and Medical Practices

  • 10.1 EMZL
  • 10.2 SMZL
  • 10.3 Nodal MZL
  • 10.4 Relapsing disease
  • 10.5 ESMO recently published guidelines for diagnosis, treatment, and follow-up of MZL
  • 10.6 Treatment Algorithm

11 Unmet needs

12 Marketed Drugs

  • 12.1 Revlimid (lenalidomide) in combination with rituximab: Celgene Corporation, Bristol-Myers Squibb
    • 12.1.1 Drug Description
    • 12.1.2 Regulatory Milestones
    • 12.1.3 Clinical Development
    • 12.1.4 Safety and Efficacy
    • 12.1.5 Product Profile
  • 12.2 Imbruvica (ibrutinib): AbbVie, Janssen Biotech
    • 12.2.1 Drug Description
    • 12.2.2 Regulatory Milestones
    • 12.2.3 Clinical Development
    • 12.2.4 Safety and Efficacy
    • 12.2.5 Product Profile

13 Emerging Drugs

  • 13.1 Key Cross Competition
  • 13.2 Umbralisib (TGR-1202): TG Therapeutics
    • 13.2.1 Product Description
    • 13.2.2 Other Developmental Activities
    • 13.2.3 Clinical Development
    • 13.2.4 Safety and Efficacy
    • 13.2.5 Product Profile
  • 13.3 Aliqopa (Copanlisib): Bayer
    • 13.3.1 Product Description
    • 13.3.2 Other Developmental Activities
    • 13.3.3 Clinical Development
    • 13.3.4 Safety and Efficacy
    • 13.3.5 Product Profile
  • 13.4 Ublituximab: TG Therapeutics
    • 13.4.1 Product Description
    • 13.4.2 Other Developmental Activities
    • 13.4.3 Clinical Development
    • 13.4.4 Safety and Efficacy
    • 13.4.5 Product Profile
  • 13.5 Obinutuzumab: Roche Pharma
    • 13.5.1 Product Description
    • 1.2.3 Other Developmental Activities
    • 13.5.2 Clinical Development
    • 13.5.3 Safety and Efficacy
    • 13.5.4 Product Profile
  • 13.6 Yescarta (axicabtagene ciloleucel): Gilead Sciences
    • 13.6.1 Product Description
    • 13.6.2 Other Developmental Activities
    • 13.6.3 Clinical Development
    • 13.6.4 Safety and Efficacy
    • 13.6.5 Product Profile
  • 13.7 Keytruda (Pembrolizumab): Merck Sharp & Dohme
    • 13.7.1 Product Description
    • 13.7.2 Other Developmental Activities
    • 13.7.3 Clinical Development
    • 13.7.4 Product Profile
  • 13.8 CLR 131: Cellectar Biosciences
    • 13.8.1 Product Description
    • 13.8.2 Other Developmental Activities
    • 13.8.3 Clinical Development
    • 13.8.4 Safety and Efficacy
    • 13.8.5 Product Profile
  • 13.9 Parsaclisib: Innovent Biologics
    • 13.9.1 Product Description
    • 13.9.2 Other Developmental Activities
    • 13.9.3 Clinical Development
    • 13.9.4 Safety and Efficacy
    • 13.9.5 Product Profile
  • 13.1 Nivolumab (Oppdivo): Bristol-Myers Squibb
    • 13.10.1 Product Description
    • 13.10.2 Clinical Development
    • 13.10.3 Safety and Efficacy
    • 13.10.4 Product Profile
  • 13.11 Calquence (acalabrutinib): Astrazeneca
    • 13.11.1 Product Description
    • 13.11.2 Clinical Development
    • 13.11.3 Product Profile
  • 13.12 Betalutin (177Lu-satetraxetan-lilotomab): Nordic Nanovector
    • 13.12.1 Product Description
    • 13.12.2 Other Developmental Activities
    • 13.12.3 Clinical Development
    • 13.12.4 Safety and Efficacy
    • 13.12.5 Product Profile
  • 13.13 Navitoclax (ABT-263): AbbVie
    • 13.13.1 Product Description
    • 13.13.2 Clinical Development
    • 13.13.3 Safety and Efficacy
    • 13.13.4 Product Profile
  • 13.14 Orelabrutinib (ICP-022): InnoCare Pharma
    • 13.14.1 Product Description
    • 13.14.2 Other Developmental Activities
    • 13.14.3 Clinical Development
    • 13.14.4 Product Profile
  • 13.15 M7583: Merck KGaA
    • 13.15.1 Product Description
    • 13.15.2 Other Developmental Activities
    • 13.15.3 Clinical Development
    • 13.15.4 Safety and Efficacy
    • 13.15.5 Product Profile
  • 13.16 ARQ 531: ArQule/Merck
    • 13.16.1 Product Description
    • 13.16.2 Other Developmental Activities
    • 13.16.3 Clinical Development
    • 13.16.4 Safety and Efficacy
    • 13.16.5 Product Profile
  • 13.17 Duvelisib: Verastem/Secura Bio
    • 13.17.1 Product Description
    • 13.17.2 Other Developmental Activities
    • 13.17.3 Clinical Development
    • 13.17.4 Safety and Efficacy
    • 13.17.5 Product Profile
  • 13.18 Zanubrutinib: BeiGene
    • 13.18.1 Product Description
    • 13.18.2 Other Developmental Activities
    • 13.18.3 Clinical Development
    • 13.18.4 Safety and Efficacy
    • 13.18.5 Product Profile
  • 13.19 Zandelisib: MEI Pharma
    • 13.19.1 Product Description
    • 13.19.2 Other Developmental Activities
    • 13.19.3 Clinical Development
    • 13.19.4 Safety and Efficacy
    • 13.19.5 Product Profile
  • 13.20 ALT-803: NantKwest/ImmunityBio
    • 13.20.1 Product Description
    • 13.20.2 Other Developmental Activities
    • 13.20.3 Clinical Development
    • 13.20.4 Safety and Efficacy
    • 13.20.5 Product Profile
  • 13.21 LOXO-305: Loxo Oncology/Eli Lilly
    • 13.21.1 Product Description
    • 13.21.2 Other Developmental Activities
    • 13.21.3 Clinical Development
    • 13.21.4 Safety and Efficacy
    • 13.21.5 Product Profile
  • 13.22 SD-101: TriSalus Life Sciences
    • 13.22.1 Product Description
    • 13.22.2 Other Developmental Activities
    • 13.22.3 Clinical Development
    • 13.22.4 Safety and Efficacy
    • 13.22.5 Product Profile

14 Patient Journey

15 Marginal Zone Lymphoma (MZL): 7MM Analysis

  • 15.1 Key Findings
  • 15.2 Market Methodology
  • 15.3 Market Size of Marginal Zone Lymphoma (MZL) in the 7MM
  • 15.4 Market Size of Marginal Zone Lymphoma (MZL) by Line of Therapies in the 7MM
    • 15.4.1 Market Size of Marginal Zone Lymphoma (MZL) by First-line therapies in the 7MM
    • 15.4.2 Market Size of Marginal Zone Lymphoma (MZL) by Second-line therapies in the 7MM
    • 15.4.3 Market Size of Marginal Zone Lymphoma (MZL) by Third-line therapies in the 7MM

16 Potential of Emerging Therapies

17 Key Market Forecast Assumptions

18 7MM Market Outlook

19 United States

  • 19.1 United States Market Size
    • 19.1.1 Total market size of Marginal Zone Lymphoma (MZL) in the United States
    • 19.1.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of Therapies in the US

20 EU-5 Countries

  • 20.1 Germany Market Size
    • 20.1.1 Total Market size of Marginal Zone Lymphoma (MZL) in Germany
    • 20.1.2 Market Size of Marginal Zone Lymphoma (MZL) by line of therapies in Germany
  • 20.2 France Market Size
    • 20.2.1 Total Market size of Marginal Zone Lymphoma (MZL) in France
    • 20.2.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of therapies in France
  • 20.3 Italy Market Size
    • 20.3.1 Total Market size of Marginal Zone Lymphoma (MZL) in Italy
    • 20.3.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of therapies in Italy
  • 20.4 Spain Market Size
    • 20.4.1 Total Market size of Marginal Zone Lymphoma (MZL) in Spain
    • 20.4.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of therapies in Spain
  • 20.5 United Kingdom Market Size
    • 20.5.1 Total Market size of Marginal Zone Lymphoma (MZL) in the United Kingdom
    • 20.5.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of therapies in the UK

21 Japan

  • 21.1 Japan Market Size
    • 21.1.1 Total Market size of Marginal Zone Lymphoma (MZL) in Japan
    • 21.1.2 Market Size of Marginal Zone Lymphoma (MZL) by line of therapies in Japan

22 Market Drivers

23 Market Barriers

24 SWOT Analysis

25 Reimbursement and Market access

26 Recognized Establishments

27 Appendix

  • 27.1 Bibliography
  • 27.2 Report Methodology

28 DelveInsight Capabilities

29 Disclaimer

30 About DelveInsight

Back to Top
전화 문의
F A Q